DE602004014773D1 - Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors - Google Patents

Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors

Info

Publication number
DE602004014773D1
DE602004014773D1 DE602004014773T DE602004014773T DE602004014773D1 DE 602004014773 D1 DE602004014773 D1 DE 602004014773D1 DE 602004014773 T DE602004014773 T DE 602004014773T DE 602004014773 T DE602004014773 T DE 602004014773T DE 602004014773 D1 DE602004014773 D1 DE 602004014773D1
Authority
DE
Germany
Prior art keywords
pyrrol
liver
receptor modulators
dion derivatives
dion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004014773T
Other languages
English (en)
Inventor
Jonas Bostroem
Kay Brickmann
Patrik Holm
Pernilla Sandberg
Marianne Swanson
Christer Westerlund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE602004014773D1 publication Critical patent/DE602004014773D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DE602004014773T 2003-07-11 2004-07-08 Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors Expired - Fee Related DE602004014773D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316232.8A GB0316232D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
PCT/SE2004/001114 WO2005005417A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators

Publications (1)

Publication Number Publication Date
DE602004014773D1 true DE602004014773D1 (de) 2008-08-14

Family

ID=27741983

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004014773T Expired - Fee Related DE602004014773D1 (de) 2003-07-11 2004-07-08 Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors

Country Status (26)

Country Link
US (1) US7432288B2 (de)
EP (1) EP1646626B1 (de)
JP (1) JP2007521312A (de)
KR (1) KR20060035748A (de)
CN (1) CN1823061A (de)
AR (1) AR045721A1 (de)
AT (1) ATE399777T1 (de)
AU (1) AU2004255999B2 (de)
BR (1) BRPI0412472A (de)
CA (1) CA2532056A1 (de)
DE (1) DE602004014773D1 (de)
ES (1) ES2308204T3 (de)
GB (1) GB0316232D0 (de)
HK (1) HK1088320A1 (de)
IL (1) IL172760A0 (de)
IS (1) IS8293A (de)
MX (1) MXPA06000414A (de)
MY (1) MY135821A (de)
NO (1) NO20060081L (de)
RU (1) RU2006102130A (de)
SA (1) SA04250204B1 (de)
TW (1) TW200503691A (de)
UA (1) UA82109C2 (de)
UY (1) UY28408A1 (de)
WO (1) WO2005005417A1 (de)
ZA (1) ZA200600222B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE513823T1 (de) * 2004-08-17 2011-07-15 Simpson Biotech Co Ltd Mischung und verbindungen von mycelien von antrodia camphorata und deren verwendung
US7505238B2 (en) * 2005-01-07 2009-03-17 Agnes Neves Woo ESD configuration for low parasitic capacitance I/O
JP2008526841A (ja) 2005-01-10 2008-07-24 アストラゼネカ アクチボラグ 肝臓ｘ受容体調節因子としてのイソチアゾール−３（２ｈ）−オン１，１−ジオキシドのアニリン系誘導体
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
CA2640806A1 (en) * 2006-04-28 2007-11-15 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
KR101475088B1 (ko) 2006-08-21 2014-12-23 제넨테크, 인크. 아자-벤조티오페닐 화합물 및 사용 방법
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途
CN102137843A (zh) 2008-07-01 2011-07-27 健泰科生物技术公司 作为mek激酶抑制剂的异吲哚酮衍生物及其使用方法
CN102137847B (zh) 2008-07-01 2015-06-10 健泰科生物技术公司 作为mek激酶抑制剂的二环杂环
EP2615094A4 (de) 2010-09-07 2013-09-18 Snu R&Db Foundation Sesterterpenverbindungen und ihre verwendung
CA2819609A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
CA2819603A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Novel oxime derivatives as sphingosine 1-phosphate (s1p) receptor modulators
CA2939120A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
MX2022007164A (es) 2019-12-13 2022-09-12 Inspirna Inc Sales metálicas y usos de estas.
WO2022109066A1 (en) * 2020-11-18 2022-05-27 Southern Research Institute Compounds for the treatment of acute and chronic kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010085305A (ko) 1998-07-30 2001-09-07 미즈노 마사루 이치환된 말레이미드 화합물 및 그의 의약 용도
ES2234300T3 (es) * 1998-10-08 2005-06-16 Smithkline Beecham Plc 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
CA2377999A1 (en) * 1999-07-08 2001-01-18 Tularik Inc Compositions and methods for raising hdl cholesterol levels
EP1224932A4 (de) 1999-08-20 2002-10-16 Sagami Chem Res Wirkstoffe zur hemmung des zelltods
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
SA04250204B1 (ar) 2008-03-23
AU2004255999A1 (en) 2005-01-20
GB0316232D0 (en) 2003-08-13
EP1646626A1 (de) 2006-04-19
ZA200600222B (en) 2007-04-25
HK1088320A1 (en) 2006-11-03
CN1823061A (zh) 2006-08-23
KR20060035748A (ko) 2006-04-26
US7432288B2 (en) 2008-10-07
NO20060081L (no) 2006-02-08
EP1646626B1 (de) 2008-07-02
BRPI0412472A (pt) 2006-09-19
WO2005005417A1 (en) 2005-01-20
TW200503691A (en) 2005-02-01
AU2004255999B2 (en) 2007-08-02
JP2007521312A (ja) 2007-08-02
IL172760A0 (en) 2006-04-10
US20060235015A1 (en) 2006-10-19
IS8293A (is) 2006-02-09
UY28408A1 (es) 2005-02-28
MXPA06000414A (es) 2006-03-17
AR045721A1 (es) 2005-11-09
ATE399777T1 (de) 2008-07-15
MY135821A (en) 2008-07-31
ES2308204T3 (es) 2008-12-01
UA82109C2 (uk) 2008-03-11
RU2006102130A (ru) 2007-08-20
CA2532056A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
LTC1725537I2 (lt) Nauji junginiai, kaip opioido receptoriaus moduliatoriai
ZA200600229B (en) Pyrrole-2,5-dithione derivatives as Liver X receptor modulators
IL172760A0 (en) Pyrrole-2,5-dithione derivatives as liver x receptor modulators
ATE439357T1 (de) Indolylderivate als liver-x-rezeptormodulatoren
GB0419481D0 (en) Isoindolin-1-one derivatives
NO20053748D0 (no) Pyrrolopyridazinderivater.
IL180630A0 (en) Pyrrole derivatives as pharmaceutical agents
ATE440085T1 (de) 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
EP1790650A4 (de) Neue substituierte imidazolderivate
EP1812585A4 (de) Bakteriophagen als selektive wirkstoffe
DK1802307T3 (da) Pyrrolidinderivater som histamin-receptor-ligander
IL183140A0 (en) Substituted benzoquinolizine derivatives
EP1799640A4 (de) Als serotoninselektive wirkstoffe geeignete indolverbindungen
ZA200700352B (en) Pyrrole derivatives as pharmaceutical agents
ZA200609234B (en) Substituted azeplne derivatives as serotonin receptor modulators
HK1114841A1 (en) Phenyl-piperazin methanone derivatives
IL182739A0 (en) Acylatednonadepsipeptides used as lysobactin derivatives
BRPI0509256A (pt) derivados de pirrolidina-3,4-dicarboxamida
DE502005002049D1 (de) Schmales, seitlich aneinanderreihbares wägesystem
ATE398620T1 (de) Spirokondensierte indolinderivate als pestizide
ES1058483Y (es) Bloque de asientos perfeccionado.
IL165408A0 (en) Novel substituted indoles
GB0418691D0 (en) N -Substituted willardiine derivatives as selective GLUK5 modulating agents
ES1056631Y (es) Accesorio de sujecion de cuellos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee